Researchers at Purdue University recently reported on an extrusion-based approach where the dissolution rate of poorly soluble
drugs (griseofulvin, phenytoin, and spironolactone) was improved through solid crystal suspensions. The drug and mannitol
were coprocessed in a hot-melt extrusion operation. The resulting product was a mixture of the crystalline drug and crystalline excipient, with up to 50% (w/w) drug load. The in vitro drug release from the obtained solid crystalline suspensions was more than two orders of magnitude faster than that of the
pure drug. The researchers reported that because the resulting product was crystalline, the accelerated dissolution rate did
have the physical stability concerns as with amorphous formulations. The researchers reported this approach is useful in situations
where the drug is not a good glass former or in cases where it is difficult to stabilize the amorphous drug (4).
1. P. Van Arnum, Pharm. Technol. 35 (10), 50–56 (2010).
2. J. Doney and J. Yang, Pharm. Technol. 32 (7), 96–98 (2008).
3. M. Karl, D. Djuric, and J. Kolter, Pharm. Technol. 35 (5), 74–82 (2011).
4. M. Thommers et al., Mol. Pharmaceutics
8 (3), 727–735 (2011).